Search results | colorectal cancer


Colorectal Cancer Partnering

The Colorectal Cancer Partnering provides understanding and access to the colorectal cancer partnering deals and agreements entered into by the worlds leading healthcare companies


AstraZeneca and Pfizer in the news for another possible m&a bid

AstraZeneca stock rose two percent to £45.67 pounds yesterday after the Swedish newspaper Dagens Industry suggested another possible Pfizer m&a  bid. AstraZeneca stocks have risen 9.5% in the last week, following a stream of good news regarding its pipeline and takeover bids by Pfizer.

Top 15 most partnered therapeutic trends in pharma industry

Current Partnering releases its first update of the article previously published last year on the most partnered therapeutic trends in pharma. The article analyses the most partnered therapeutic targets of 2009-2014 and identifies the areas that have gained in popularity since last year and the new areas that have entered the list

Oncology partnering – recent deals analysis 2009-2014

Partnering in the last decade has seen an increase in oncology partnering with an increase in modern diagnostic technologies, according to recent partnering deals analysis

Spectrum Pharmaceuticals: Where partnering IS the business model

Spectrum Pharmaceuticals is a biotechnology company providing key oncology and haematology products for patients around the world.

Oncology partnering

A focus on oncology partnering for therapies, diagnostics and other interventions for the treatment and prevention of cancer

Therapeutic partnering

Partnering with a therapeutic end point in mind.

Regeneron Pharmaceuticals : Right technology, right time

Regeneron Pharmaceuticals is Biopharmaceutical Company focusing on the development of human antibody technologies for the treatment of a number of different diseases.

Top 15 Most Partnered Therapeutic Targets

A recent study by Current Partnering identifies the most partnered therapeutic targets in recent years. Updated version of this article available here Top 15 most partnered therapeutic trends in pharma industry 2014

Industry trends in vaccine dealmaking – 2007 to 2013

Industry trends suggest that vaccine research and development is an increasingly active component of healthcare business development. In recent years there has been a significant increase in vaccine partnering and M&A activity

Sanofi acquisition of Regeneron a possibility?

Acquisition possibility? Sanofi and Regeneron are already partners with CEO Chris Viehbachers intent on new deals


Sorry, your search returned no results.


Almac Diagnostics in collaboration with Pfizer and PETACC3 Translational Research Working Party for molecular subtyping and biomarker identification in colorectal cancer

The aims of the study are to identify molecular subtypes in colorectal cancer and to identify new drug targets in treatment resistant patients.

Collaboration agreement for validating colorectal biomarker

IntegraGen announced a collaboration with investigators from the New EPOC study to validate the oncology biomarker hsamiR313p.

Merck and Enumeral predicting clinical drug response

Enumeral Biomedical has signed an oncology-focused collaborative study agreement with Merck

BMS and Five Prime partner on Opdivo – FPA008 combination

Bristol-Myers Squibb and Five Prime Therapeutics have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb’s investigational PD-1 (programmed death-1) immune checkpoint inhibitor, with FPA008

Remiges raises $30 million in venture capital financing

Taiho Pharmaceutical announced that the company will be investing US$30 million in Remiges BioPharma Fund, a newly formed biotech venture capital financing.

Qiagen and Eli Lilly sign a biotech deal for biomarkers

QIAGEN announced a collaboration on a biotech deal with Eli Lilly and Company to co-develop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types.

Exact Sciences raises $137.7 million in public offering financing

Exact Sciences has completed a secondary stock offering, selling 11.5 million shares of common stock.

Pharma deal between Illumina and Amgen

Illumina has entered into an pharma deal agreement with Amgen to develop and commercialize a multigene, NGS-based test as a companion diagnostic for Vectibix (panitumumab).

Applied Proteomics in $28 million Series C financing

Applied Proteomics announces the closing of its $28 million dollar Series C financing.

Amgen pharma deals with Zhejiang Beta Pharma in joint venture

Amgen pharma deals with Zhejiang Beta Pharma to form a joint venture that will commercialize Amgen’s Vectibix in the Chinese market.